Correlation of Increased Vascular Endothelial Growth Factor With Neovascularization and Permeability in Ischemic Central Vein Occlusion

Abstract

To establish a role for vascular endothelial growth factor (VEGF) during the onset and clinical course of neovascularization of the iris (NVI) in ischemic central retinal vein occlusion. Methods: Sixteen patients with ischemic central retinal vein occlusion were followed up for 12 months by clinical examination, retinal and iris angiography, and serial anterior chamber sampling of aqueous humor. Aqueous VEGF level was determined by enzyme-linked immunoassay, and permeability changes were estimated by capillary zone electrophoretic assessment of aqueous albumin. Results: A correlation was found between aqueous VEGF concentrations and the onset, persistence, and regression of NVI; extent of retinal capillary nonperfusion; and vascular permeability. The NVI occurred when aqueous VEGF concentrations were 849 to 1569 pg/mL and re-CLINICAL SCIENCES

Five-year outcomes of retinal vein occlusion treated with vascular endothelial growth factor inhibitors

“…In our cohort, even in those without complete resolution of macular oedema, vision was ≥50 letters in 84% of non-ischaemic CRVO and 67% of those with ischaemic CRVO. This reflects the hypothesised association between retinal ischaemia and increased production of VEGF,40 with many studies reporting reperfusion of ischaemic retina with anti-VEGF treatment 41–43…”

Five-year outcomes of retinal vein occlusion treated with vascular endothelial growth factor inhibitors

“…In our cohort, even in those without complete resolution of macular oedema, vision was ≥50 letters in 84% of non-ischaemic CRVO and 67% of those with ischaemic CRVO. This reflects the hypothesised association between retinal ischaemia and increased production of VEGF,40 with many studies reporting reperfusion of ischaemic retina with anti-VEGF treatment 41–43…”

Risk of newly developing visual field defect and neurodegeneration after pars plana vitrectomy for idiopathic epiretinal membrane

“…However, most (93%) eyes were injected with brilliant Blue G even when the ILM was not peeled; in these eyes, the injection was performed to confirm that the ILM was not peeled. Brilliant blue G was reported to be safer than ICG in a neural cell line, 25 and its intravitreal injection did not cause RGC reduction 26 or visual function impairment as measured by electroretinography. 26 27 The safety was also analysed by comparing it with ICG and trypan blue, by injecting Brilliant Blue G into the subretinal space to find no apoptotic cells in the outer and inner layers of the retina and the RPE in animals.…”

The Related Transcriptional Enhancer Factor-1 Isoform, TEAD4216, Can Repress Vascular Endothelial Growth Factor Expression in Mammalian Cells

“…[18], [19] Analysis of retinal, choroidal and iris tissue for TEAD4 RNA in a non-human primate (NHP) model of central retinal artery occlusion (CRAO) indicated that the TEAD4 434 form of TEAD4 was upregulated in the ischemic eye and undetectable in the contralateral control eye (Figure 9). In addition, the NHP orthologue of the human TEAD4 148 isoform was found to be present in iris tissue from the ischemic eye and not in the normal control eye (Figure 9).…”

Five-year outcomes of retinal vein occlusion treated with vascular endothelial growth factor inhibitors

“…In our cohort, even in those without complete resolution of macular oedema, vision was ≥50 letters in 84% of non-ischaemic CRVO and 67% of those with ischaemic CRVO. This reflects the hypothesised association between retinal ischaemia and increased production of VEGF,40 with many studies reporting reperfusion of ischaemic retina with anti-VEGF treatment 41–43…”

Risk of newly developing visual field defect and neurodegeneration after pars plana vitrectomy for idiopathic epiretinal membrane

“…However, most (93%) eyes were injected with brilliant Blue G even when the ILM was not peeled; in these eyes, the injection was performed to confirm that the ILM was not peeled. Brilliant blue G was reported to be safer than ICG in a neural cell line, 25 and its intravitreal injection did not cause RGC reduction 26 or visual function impairment as measured by electroretinography. 26 27 The safety was also analysed by comparing it with ICG and trypan blue, by injecting Brilliant Blue G into the subretinal space to find no apoptotic cells in the outer and inner layers of the retina and the RPE in animals.…”

The Related Transcriptional Enhancer Factor-1 Isoform, TEAD4216, Can Repress Vascular Endothelial Growth Factor Expression in Mammalian Cells

“…[18], [19] Analysis of retinal, choroidal and iris tissue for TEAD4 RNA in a non-human primate (NHP) model of central retinal artery occlusion (CRAO) indicated that the TEAD4 434 form of TEAD4 was upregulated in the ischemic eye and undetectable in the contralateral control eye (Figure 9). In addition, the NHP orthologue of the human TEAD4 148 isoform was found to be present in iris tissue from the ischemic eye and not in the normal control eye (Figure 9).…”

Five-year outcomes of retinal vein occlusion treated with vascular endothelial growth factor inhibitors

“…In our cohort, even in those without complete resolution of macular oedema, vision was ≥50 letters in 84% of non-ischaemic CRVO and 67% of those with ischaemic CRVO. This reflects the hypothesised association between retinal ischaemia and increased production of VEGF,40 with many studies reporting reperfusion of ischaemic retina with anti-VEGF treatment 41–43…”

Risk of newly developing visual field defect and neurodegeneration after pars plana vitrectomy for idiopathic epiretinal membrane

“…However, most (93%) eyes were injected with brilliant Blue G even when the ILM was not peeled; in these eyes, the injection was performed to confirm that the ILM was not peeled. Brilliant blue G was reported to be safer than ICG in a neural cell line, 25 and its intravitreal injection did not cause RGC reduction 26 or visual function impairment as measured by electroretinography. 26 27 The safety was also analysed by comparing it with ICG and trypan blue, by injecting Brilliant Blue G into the subretinal space to find no apoptotic cells in the outer and inner layers of the retina and the RPE in animals.…”

The Related Transcriptional Enhancer Factor-1 Isoform, TEAD4216, Can Repress Vascular Endothelial Growth Factor Expression in Mammalian Cells

“…[18], [19] Analysis of retinal, choroidal and iris tissue for TEAD4 RNA in a non-human primate (NHP) model of central retinal artery occlusion (CRAO) indicated that the TEAD4 434 form of TEAD4 was upregulated in the ischemic eye and undetectable in the contralateral control eye (Figure 9). In addition, the NHP orthologue of the human TEAD4 148 isoform was found to be present in iris tissue from the ischemic eye and not in the normal control eye (Figure 9).…”